Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan ODT bioavailability study in healthy volunteers
NCT06831344Phase 1Completed
- Sponsor
- Phathom Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vonoprazan (5 arms), sponsored by Phathom Pharmaceuticals. Primary endpoints: Maximum Observed Drug Concentration at 48 hours, Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration at 48 hours and 1 more. Started Feb 2025; status: completed.
02
Drugs
vonoprazan
Beyond the preview
Go deeper on NCT06831344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06831344.